Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion

Long‐term results of organ transplantation are still limited by serious side effects of immunosuppressive drugs. A major issue, therefore, is to elaborate novel therapeutic protocols allowing withdrawal or minimization of immunosuppressive therapy after transplantation. We report on 3 patients prospectively enrolled in an original protocol designed to promote graft acceptance in living donor liver transplantation, using posttransplant conditioning with high doses of antithymocyte globulin followed by injection of donor‐derived stem cells. In 2 patients, early immunosuppression withdrawal was possible, without subsequent graft deterioration. In these 2 cases, in vitro studies showed indices of immunological tolerance as assessed by specific hyporesponsiveness to donor alloantigens in mixed lymphocytes culture. In the third patient, acute rejection rapidly occurred after discontinuation of immunosuppression, and minimal immunosuppression has to be maintained during long‐term follow‐up. In this case, a clearly distinct immunoreactive profile was observed as compared to tolerant patients, as no specific modulation of the antidonor response was observed in vitro. Of note, no macrochimerism could be detected in any of the 3 patients during the follow‐up. In conclusion, these clinical observations demonstrated that, despite the absence of macrochimerism, donor stem cells infusion combined with recipient conditioning may allow early immunosuppression withdrawal or minimization after liver transplantation. Liver Transpt 12:1523–1528, 2006. © 2006 AASLD.

[1]  M. Andrien,et al.  A rapid test to monitor alloreactive responses in whole blood using real-time polymerase chain reaction. , 2005, Transplantation.

[2]  N. Heaton,et al.  Long-term outcome of immunosuppression withdrawal after liver transplantation. , 2005, Transplantation proceedings.

[3]  J. Moon,et al.  The Role of Donor Bone Marrow Infusions in Withdrawal of Immunosuppression in Adult Liver Allotransplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  T. Starzl,et al.  Use of Alemtuzumab and Tacrolimus Monotherapy for Cadaveric Liver Transplantation: With Particular Reference to Hepatitis C Virus , 2004, Transplantation.

[5]  I. Colle,et al.  Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. , 2004, Transplant immunology.

[6]  D. Adams,et al.  DEMONSTRATION THAT DONOR-SPECIFIC NONRESPONSIVENESS IN HUMAN LIVER ALLOGRAFT RECIPIENTS IS BOTH RARE AND TRANSIENT , 2004, Transplantation.

[7]  M. Sykes,et al.  Induction of tolerance. , 2004, Surgery.

[8]  A. Kirk Ethics in the quest for transplant tolerance. , 2004, Transplantation.

[9]  R. Zinkernagel,et al.  Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. , 2003, Transplantation.

[10]  Paulo Fontes,et al.  Tolerogenic immunosuppression for organ transplantation , 2003, The Lancet.

[11]  A. Berrebi,et al.  Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34(+) cells. , 2002, Blood.

[12]  F. Delmonico,et al.  Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. , 1999, Transplantation.

[13]  R. Rubin,et al.  Infection in organ-transplant recipients. , 1998, The New England journal of medicine.

[14]  B. Portmann,et al.  Defining the outcome of immunosuppression withdrawal after liver transplantation , 1998, Hepatology.

[15]  B. Dréno,et al.  Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens , 1998, The Lancet.

[16]  A. Monaco,et al.  Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow. , 1998, Transplantation.

[17]  E. Schiff,et al.  High-dose donor bone marrow infusions to enhance allograft survival: the effect of timing. , 1997, Transplantation.

[18]  H. Rennke,et al.  Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. , 1991, Annals of internal medicine.

[19]  R. Garibaldi Infections in Organ Transplant Recipients , 1983, Infection Control.

[20]  M. Morita,et al.  FK 506 inhibits tolerance induction in mice liver transplantation , 2005 .

[21]  ndrea,et al.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. , 1996, The New England journal of medicine.

[22]  Neha Garg,et al.  Living donor liver , 2022 .